|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
0.3688 USD |
+4.94% | +0.79% | +23.34% | |
Published on 06/18/2025 at 17:57
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Cellectar Biosciences announces one-for-thirty reverse stock split |
05:57pm |
RE |
|
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 |
04:50pm |
MT |
|
Cellectar Biosciences Provides Update on Clover-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma |
Jun. 11 |
CI |
|
Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise |
Jun. 05 |
MT |
|
Cellectar Biosciences, Inc. Grants U.S. Fda Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia |
Jun. 04 |
CI |
|
Cellectar Biosciences Says FDA Granted Breakthrough Therapy Designation for Experimental Cancer Drug; Shares Rise Pre-Bell |
Jun. 04 |
MT |
|
Cellectar Biosciences, Inc., Q1 2025 Earnings Call, May 13, 2025 |
May. 13 |
|
|
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 13 |
CI |
|
Cellectar Biosciences Announces Plan to Explore Strategic Alternatives to Maximize Stockholder Value |
Apr. 30 |
CI |
|
Cellectar Announces Plan To Explore Strategic Alternatives |
Apr. 30 |
RE |
|
Cellectar Biosciences, Inc., 2024 Earnings Call, Mar 13, 2025 |
Mar. 13 |
|
|
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 13 |
CI |
|
Cellectar Biosciences, Inc. Auditor Raises ‘Going Concern’ Doubt |
Mar. 12 |
CI |
|
Cellectar Biosciences, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 11:30 AM |
Jan. 14 |
|
|
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut |
Dec. 11 |
DJ |
|
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring |
Dec. 10 |
CI |
|
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $14, Maintains Outperform Rating |
Nov. 19 |
MT |
|
Cellectar Biosciences, Inc., Q3 2024 Earnings Call, Nov 18, 2024 |
Nov. 18 |
|
|
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 18 |
CI |
|
Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024 |
Nov. 07 |
CI |
|
Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-10-29 |
CI |
|
Cellectar Biosciences, Inc. Auditor Raises ‘Going Concern’ Doubt |
24-10-28 |
CI |
|
Cellectar Biosciences, Inc., Q2 2024 Earnings Call, Aug 13, 2024 |
24-08-13 |
|
|
Cellectar Biosciences, Inc. – Special Call |
24-07-24 |
|
|
Cellectar Shares Fall as Updated Data For Investigational Radiotherapy Shows Drop in Major Response Rate |
24-07-23 |
MT |
CLRB: Dynamic Chart
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
More about the company
Buy
Last Close Price
0.3514USD
Average target price
4.000USD
Spread / Average Target
+1,038.30%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
